.jpeg "Zydus & RK Pharma Sign US Oncology 505(b)(2) Licensing Pact")
Zydus Lifesciences, a global innovation-driven healthcare company, today announced that it has entered into an exclusive licensing and commercialization agreement with RK Pharma Inc of the US for a novel sterile injectable 505(b)(2) oncology supporti
Novo Nordisk’s obesity drug amycretin delivered a major boost to the company today, after new mid-stage trial results showed the treatment helped patients with type 2 diabetes lose up to 14.5% of their weight in 36 weeks. The update quickly...
Zydus Lifesciences Limited has got the final approval of FDA on its Verapamil Hydrochloride Extended-Release Tablets in 120 mg, 180 mg and 240 mg strengths. This authorization authorizes the firm to sell a new generic copy of the medication...
Abbott has announced a medical device correction for select FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the U.S., after internal testing revealed that some units may deliver incorrect low glucose readings.The company says this flaw...
Eris Lifesciences announced that its board has sanctioned the purchase of the remaining 30 percent share in its subsidiary Swiss Parenterals
Saviynt, the worldwide leader in AI-driven identity security and governance solutions, revealed that Narayana Health, one of India’s largest and most trusted healthcare networks, has implemented the Saviynt Identity Cloud to upgrade identity
Apollo Hospitals opened its latest healthcare facility in Swargate, Pune, on Monday, marking its third hospital in Maharashtra and further expanding its presence in western India
.png "Lilly Unveils New Breakthrough Data in HR+ Breast Cancer at SABCS")
Eli Lilly and Company is preparing to unveil a slate of new findings at the San Antonio Breast Cancer Symposium (SABCS), running December 9–12. The update shines a spotlight on fresh progress in HR+ breast cancer, the most common form of the...
Bayer reported a major step forward today as its experimental drug asundexian reduced the risk of recurrent ischemic stroke without increasing bleeding risk in a global phase III study. The OCEANIC-STROKE trial hit both its primary efficacy and...
The European Commission has approved the denosumab biosimilar AVT03 marketing. This license allows the Dr.?Reddy’s Laboratories to provide new options of treatment all over the EU and the European Economic Area...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")